Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25653338 | 0.87 | LRRK2 (0.47) | LRRK2HRH4HRH3 | |
| SCHEMBL11960312 | 0.86 | LRRK2 (0.48) | LRRK2 | |
| SCHEMBL11960308 | 0.82 | HRH4 (0.53) | HRH4HRH3HRH2 | |
| SCHEMBL25951462 | 0.81 | LRRK2 (0.47) | LRRK2HRH4HRH3KITFLT3 | |
| SCHEMBL11960323 | 0.78 | SMN1; SMN2 (0.46) | LRRK2HRH4HRH3 | |
| SCHEMBL13034784 | 0.77 | SMN1; SMN2 (0.49) | LRRK2HRH4HRH3 | |
| SCHEMBL16903679 | 0.76 | LRRK2 (0.44) | LRRK2 | |
| SCHEMBL10223327 | 0.74 | CYP2C19 (0.58) | LRRK2 | |
| SCHEMBL11981505 | 0.74 | LRRK2 (0.46) | LRRK2KIT | |
| SCHEMBL11960332 | 0.72 | LRRK2 (0.43) | LRRK2HRH4HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | LRRK2, FABP7, PARK7 | LRRK2 1/4885HRH4 4444/4885HRH3 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.